SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Neurex Corporation
An SI Board Since December 1996
Posts SubjectMarks Bans Symbol
449 4 0 NXCO
Emcee:  ChinuSFO Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
74 I was introduced to this stock by the Worth article and bought in a few days agCody Goebel-2/16/1997
73 The article was extremely favorable. Lets put it this way, they were comparingJames Silverman-2/12/1997
72 it sounds like it was neutral rather than favorable, you sited the promise of Scl-2/12/1997
71 Confused by what? After reading it, you'll see how NXCO really lucked intJames Silverman-2/11/1997
70 James, I am a little confused by your last post. But anyway, I would take a locl-2/11/1997
69 I was surprised at the lack of response. A few things struck me in the articlJames Silverman-2/11/1997
68 James, I agree. Excellent article. I expect some reaction. GilGil Kempenich-2/11/1997
67 Very favorable article in Worth Magazine on NXCO. Its actually quite an extenJames Silverman-2/11/1997
66 Thanks Jeffers. I have been to their talks before, all sounded very promising.cl-2/11/1997
65 cl, Neurex had a company meeting this afternoon about the progress of corlopam.Jeffers Hughes-2/11/1997
64 Bill, you have right, it is agonist. I should be more careful what I am writingMiljenko Zuanic-2/7/1997
63 I understand the very early stage status as I think you do. My understanding Bill Tomko-2/7/1997
62 Chinmoy, I'll have to look into that. The three firms that have eps estimaGiuseppe Scalamogna-2/6/1997
61 Ended, in market are several dopamine receptor antagonist for renal dysfunctionMiljenko Zuanic-2/6/1997
60 Jeff, am I reading the same news? For me, the NXCO again reported ambiguous newMiljenko Zuanic-2/6/1997
59 Regarding the CORLOPAM renal protection study, NOT THE BLOOD PRESSURE STUDY,do Bill Tomko-2/6/1997
58 cl, 'CORLOPAM Renal Program has been completed and clinical data analJeffers Hughes-2/6/1997
57 So, they finally said something... and the price did pop up a bit. This shows cl-2/5/1997
56 Wednesday February 5 8:16 AM EDT Neurex Initiates CORLOPAM Renal Program StuJeffers Hughes-2/5/1997
55 You mention about 2 buy recommendation and 1 buy/hold recommendation. Who are tChinuSFO-2/4/1997
54 To all, Perhaps this is of little significance to everyone as we all seem to bGiuseppe Scalamogna-2/4/1997
53 Neurex may address the approval status of corlopam next week. Keep a close watJeffers Hughes-2/2/1997
52 Thanks Jeffers, and everyone. I think we have the concensus that something neecl-2/2/1997
51 You may well be right. Although I do think Corlopam has been more thoroghly teJames Silverman-2/2/1997
50 I do not know (even marginally) WHEN and WHY FDA bypass advisory committee meMiljenko Zuanic-2/1/1997
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News